BioSpace News Archive

Company prepares for U.S. IDE clinical trial of its novel metal-free frame designed to reduce complications and preserve long-term treatment options

Innovative therapy targeting the root cause of the disease has received orphan drug designation by the U.S. FDA and European Medicines Agency

The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient-focused healthcare

VEGF-C shown to circumvent barriers in the brain’s lymphatic system; combination of VEGF-C and a checkpoint inhibitor promoted anti-tumor response and extended survival in preclinical model of glioblastoma

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced that in preparation for anticipated potential marketing registration filings for its drug candidates Piclidenoson and Namodenoson in the U.S. and Europe, the Company has initiated a series of preclinical studies required by regulators.

GB Sciences, Inc. and Purisys, LLC, the global industry leader in ultra-high purity, pharmaceutical grade cannabinoid supply, announced that GB Sciences has selected Purisys as their preferred vendor for the active pharmaceutical ingredients used in formulating GB Sciences’ proprietary, cannabinoid-containing, optimized therapeutic mixtures.

THCT has leveraged the extensive market research commissioned by Keyhole Research to complete two additional dHydronator® design models, one for the consumer market and one for the commercial market.

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of Genomic Medicine, at The University of Texas MD Anderson Cancer Center

Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, today reported financial results and provided a corporate update for the fourth quarter and year ended December 31, 2020.

Former COO at La Jolla Institute for Immunology to Help Drive R&D Opportunities for AIMS™ Drug Development and Discovery Technology, Including Collaboration Agreements